Calidi Biotherapeutics, Inc. (NYSE:CLDI) Shares Bought by CPR Investments Inc.

CPR Investments Inc. increased its position in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 80.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,000 shares of the company’s stock after purchasing an additional 45,000 shares during the period. CPR Investments Inc.’s holdings in Calidi Biotherapeutics were worth $116,000 at the end of the most recent quarter.

Separately, Delta Investment Management LLC grew its stake in shares of Calidi Biotherapeutics by 1,955.0% in the 2nd quarter. Delta Investment Management LLC now owns 210,230 shares of the company’s stock worth $42,000 after purchasing an additional 200,000 shares during the last quarter. 12.53% of the stock is currently owned by institutional investors.

Calidi Biotherapeutics Stock Down 3.6 %

CLDI stock opened at $0.89 on Wednesday. Calidi Biotherapeutics, Inc. has a 12 month low of $0.73 and a 12 month high of $16.80. The company’s 50 day simple moving average is $1.73.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.20. Equities analysts predict that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.